Karuna Therapeutics Inc

Karuna Therapeutics — Merger or Acquisition (December 2023)

21 slides from Karuna Therapeutics's merger presentation, Dec 22, 2023

  1. Slide 1: Bristol Myers Squibb to Acquire Karuna Therapeutics

    Bristol Myers Squibb to Acquire Karuna Therapeutics December 22, 2023

  2. Slide 2: Additional Information and Where to Find It

    Additional Information and Where to Find it In connection with the proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb, Karuna Therapeutics intends to file a preliminary and definitive proxy statement. The definitive proxy statement and proxy card will be delivered to the stockholder

  3. Slide 3: Use of Non-GAAP Financial Information and Financial Guidance

    Use of Non-GAAP Financial Information and Financial Guidance In discussing financial guidance, Bristol Myers Squibb refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The non-GAAP financial measures are provided as supplemental informat

  4. Slide 4: Our overarching goal is to achieve sustainable, top-quartile growth

    Our overarching goal is to achieve sustainable, top-quartile growth Increase company growth rate Maximize potential of the internal portfolio and pipeline Complement internal assets with disciplined business development 5

  5. Slide 5: Acquisition of Karuna expands and strengthens our presence in neuroscience

    Acquisition of Karuna expands and strengthens our presence in neuroscience while augmenting our growth profile Adds Lead Asset KarXT Potential first-in-class treatment in schizophrenia and first-in-disease treatment in Alzheimer’s disease psychosis (ADP) Antipsychotic with novel M1/M4 receptor agoni

  6. Slide 6: Karuna accelerates expansion and diversification of BMS's neuroscience portfolio

    Karuna accelerates the expansion and diversification of BMS’s neuroscience portfolio 6 FILED / APPROVED eIF2B (ALS and Alzheimer’s disease) FAAH/MGLL (Other) anti-MTBR tau (Alzheimer’s) Zeposia (MS) KarXT (Monotherapy SCZ) PDUFA Date: Sept. 26, 2024 KAR-2618 (Mood/anxiety) KarXT (Adjunctive SCZ) Kar

  7. Slide 7: KarXT: opportunity for series of indications supporting continued growth

    KarXT: Starting next year, opportunity for series of indications supporting continued growth Schizophrenia approval ~1.6M1 treated patients in the U.S. Adjunctive schizophrenia Phase 3 data Expansion within schizophrenia Alzheimer’s disease psychosis registrational data >6M2 people living with AD in

  8. Slide 8: Karuna pipeline addresses neurological and psychiatric conditions

    Karuna pipeline addresses neurological and psychiatric conditions Schizophrenia - adjunctive therapy (Registrational trial) Schizophrenia Alzheimer’s disease psychosis (Registrational acute and relapse prevention trials) Mood and anxiety disorders KarXT (xanomeline- trospium) (M1/M4 muscarinic agoni

  9. Slide 9: KarXT: Potential first-in-class antipsychotic with unique MoA

    KarXT: Potential first-in-class antipsychotic with unique MoA leading to differentiated efficacy and safety M1/M4 Unique 2-Drug Combination KarXT = Xanomeline + Trospium Xanomeline: Direct acting M1/M4 muscarinic agonist with potential to be effective in cholinergic deficient conditions Acts directl

  10. Slide 10: KarXT in schizophrenia: Compelling efficacy and differentiated safety profile

    KarXT in schizophrenia: Compelling efficacy and differentiated safety profile across three studies COMPELLING EFFICACY DIFFERENTIATED SAFETY PROFILE EMERGENT-1, 2 And 3 Trials of KarXT in Schizophrenia Primary endpoint: Change in baseline PANSS total score vs. placebo at Week 5 KarXT is not associat

  11. Slide 11: Expansion opportunities supporting future growth

    Expansion opportunities supporting future growth 10 IN REGISTRATIONAL DEVELOPMENT BY KARUNA Adjunctive schizophrenia Alzheimer’s disease psychosis Need to improve on current SOC agents KarXT has complementary MoA with differentiated safety ARISE registrational trial underway No approved therapies Co

  12. Slide 12: Indications in development comprise large patient populations and high unmet need

    Indications currently in development comprise large patient populations and high unmet need 12 SCHIZOPHRENIA ALZHEIMER’S DISEASE PSYCHOSIS ~1.6M people1 in U.S. are treated for schizophrenia ~70% of patients on current therapies are not well managed >6M people2 in the U.S. living with Alzheimer’s di

  13. Slide 13: KarXT's benefit-risk profile is clearly differentiated

    KarXT’s benefit-risk profile is clearly differentiated 13 Risperidone1 Olanzapine2 Quetiapine IR3 Aripiprazole4 Lurasidone5 Brexpiprazole6 Cariprazine7 Lumateperone8 KarXT* PANSS Placebo-subtracted difference -6.09 -8.95,10 -7.811 -8.8 -8.2 -6.5 -8.3 -5.0 -9.9 Effect size12 0.6 0.6 0.4 0.4 0.3 0.313

  14. Slide 14: We have a robust go-to-market strategy

    We have a robust go-to-market strategy 14 Patients & Caregivers HCPs: Psychiatry/NP /PAs/RNs Payers/ Medicaid/ Medicare Community Mental Health Centers Administrative Staff Building commercial readiness Patients Initially targeting patients who do not respond or cannot tolerate generic atypicals Key

  15. Slide 15: Transaction Details

    Transaction Details Purchase price: $330.00/share in an all-cash transaction ~53% premium to closing share price as of Dec. 21, 2023 Total consideration: ~$14.0B implied transaction value, net of estimated cash of ~$12.7B Will fund transaction primarily with new debt Financial overview of the acquis

  16. Slide 16: Q&A

    Q&A 16 Chris Boerner, Ph.D. Chief Executive Officer Adam Lenkowsky Executive Vice President, Chief Commercialization Officer David Elkins Executive Vice President, Chief Financial Officer Samit Hirawat, M.D. Executive Vice President, Chief Medical Officer, Global Drug Development Robert Plenge, M.D.

  17. Slide 17: BMS-KRTX Social Media Posts

    2. The following are social media posts of BMS related to the potential acquisition of Karuna by BMS, published on December 22, 2023. BMS-KRTX Social Media Posts LinkedIn:

  18. Slide 18: LinkedIn and Twitter/X post links

    FOUND AT: https://www.linkedin.com/feed/update/urn:li:activity:7143936990932078592 Twitter/X:

  19. Slide 19: Twitter/X post link

    FOUND AT: https://twitter.com/bmsnews/status/1738171282267541560

  20. Slide 20: Additional Information and Where to Find It

    FOUND AT: https://twitter.com/bmsnews/status/1738171533141369340 Additional Information and Where to Find It In connection with the proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb, Karuna Therapeutics intends to file a preliminary and definitive proxy statement. The definitive pr

  21. Slide 21: Delivering Meaningful Benefits to Patients with KarXT

    Delivering Meaningful Benefits to Patients with KarXT

Karuna Therapeutics — Merger or Acquisition (December 2023) on 6ix